Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Recurrence 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Solid Tumors Harboring NTRK Fusion 1Pancreatic Neoplasms 1Liver Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Advanced Solid Tumor 1

Interventions

Sorafenib 37Nivolumab 21pembrolizumab 18Bevacizumab 12Cyclophosphamide 10durvalumab 9fludarabine 8atezolizumab 8Magnetic Resonance Spectroscopy 8lenvatinib 7Radiosurgery 7Ipilimumab 7Radiotherapy 6Irinotecan 6Oxaliplatin 5Leucovorin 5tremelimumab 4toripalimab 4tislelizumab 4sintilimab 4cabozantinib 4budigalimab 4Specimen Handling 4Sirolimus 4Interleukin-2 4Fluorouracil 4Doxorubicin 4Capecitabine 4130-nm albumin-bound paclitaxel 4spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Hepatocellular × Receptor Protein-Tyrosine Kinases × Clear all
NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Biogen

Phase 1 Completed
40 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms

NCT01266707 2010-12-24

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Fukushima Medical University

Phase 1 Unknown
9 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡